<DOC>
	<DOCNO>NCT01285557</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy S-1 Cisplatin compare 5-FU Cisplatin treatment patient metastatic diffuse gastric esophagogastric junction cancer previously untreated chemotherapy .</brief_summary>
	<brief_title>Diffuse Gastric Esophagogastric Junction Cancer S-1 Trial</brief_title>
	<detailed_description>This open-label , international , Phase 3 study evaluate efficacy safety S-1/cisplatin regimen versus 5-FU/cisplatin regimen chemotherapy-na√Øve patient metastatic diffuse gastric carcinoma include carcinoma gastro-esophageal junction . Patients randomly assign S-1/cisplatin ( experimental regimen , Arm A ) 5-FU/cisplatin ( control regimen , Arm B ) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Has give write Informed Consent Histologically confirm , unresectable , metastatic diffuse gastric cancer include carcinoma gastroesophageal junction No prior chemotherapy gastric cancer except adjuvant and/or neoadjuvant chemotherapy 12 month ago Life expectancy least 3 month Able take medication orally ECOG performance status 0 1 Adequate organ function ( bone marrow , kidney liver ) Certain type ( ) nonmeasurable lesion ( ) , one ( ) . Certain serious illness medical condition ( ) Lost great equal 10 % body weight 3 month proceed sign ICF Treatment drug interact S1 , 5FU , cisplatin . Pregnant lactate female . Known hypersensitivity fluoropyrimidines cisplatin . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Gastric Cancer , S-1 , Phase 3</keyword>
</DOC>